ZURICH (Reuters) – Swiss pharmaceutical firm Roche isn’t planning job cuts and its enterprise is wholesome, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday.
Roche’s share value has fallen far beneath peaks it scaled in April 2022 and the CEO was questioned concerning the firm’s staffing plans within the context of current setbacks in its improvement of medication to deal with most cancers, amongst different sicknesses.
“The variety of employees is fixed to barely growing,” Schinecker instructed the NZZ am Sonntag in an interview when requested if the corporate was planning layoffs.
“I can say with certainty that we now have a really wholesome enterprise. And we do not have a development downside both,” he stated, whereas noting that Roche’s price range for analysis and improvement was steady and never rising.
Requested when Roche’s deliberate anti-obesity drug would hit the market, Schinecker stated it may very well be round 2029 or sooner.
Addressing the outlook extra broadly for subsequent yr, notably in gentle of the German financial system’s current struggles, the Roche CEO stated Europe nonetheless confronted challenges.
“There’s some financial development in the USA, however issues are tougher in China in the intervening time,” he stated. “And in Europe it can take a while earlier than we get out of this.”
